Press Release | September 09, 2014

Our Subsidiary ProBioGen celebrates the 20th anniversary: €20 million investment in Mammalian Manufacturing Expansion

Berlin, Germany, September 9, 2014 - On the occasion of its 20th anniversary,ProBioGen AG announced to invest 20€ million and to double its workforce. CEO Dr. Wieland Wolf welcomed scientific, business and political guests in a ceremony in Berlin on September 4, 2014.

On behalf of pharmaceutical and biotech companies ProBioGen is developing novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases. The service spectrum ranges from cell line and process development up to GMP contract manufacturing. In addition, the Berlin scientists develop innovative technologies to improve biotechnologically active substances and by virtue of the irrecognized scientific excellence created an extensive portfolio of proprietary rights for optimized biopharmaceutical manufacturing.

In recent times, licenses were granted to several global pharmaceutical companies, including Boehringer Ingelheim and Novartis. Beyond that, ProBioGen will further exploit its internal potential for the development of production cell lines, process engineering and GMP manufacturing of biopharmaceuticals.

"Together with our parent company, we will continue to expand and invest in Berlin," comments Dr. Wieland Wolf. "With an investment of around 20 million euros, we willstrengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees" says the CEO about ProBioGen's further growth.

Dr. Wafik Bardissi, chairman of the board, announced on behalf of MINAPHARM Pharmaceuticals to continually invest in its two biotech sites, Berlin and Cairo, and in the development of new drugs, using synergies from both sites. The primary objective is todeliver innovative and affordable medications for patients in Egypt and other low-income countries.

As part of the ceremony the ProBioGen Innovation Prize was granted by CSO Dr. Volker Sandig to molecular biologist Thomas Rose. Through his scientific research to increase cellular productivity ProBioGen now has available "super producers by stimulating the cellular secretion apparatus". Through a unique molecular biological intervention with the cell metabolism he was able to tremendously increase the cellular production capacity and thus achieve a competitive advantage for ProBioGen.


ProBioGen is a specialist for the development and manufacturing of complex therapeutic glycoproteins and viral vaccines. Combining both state-of-the-art development platforms together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing isperformed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA). ProBioGen was founded 1994, is privately owned and located in Berlin, Germany.